arXiv subjects

Jingjing Ye

Publications and source records attributed to Jingjing Ye.

5 recordsLinked to original sources

arXiv2025

Distinguishing Tidal Disruption Events and Changing-look Active Galactic Nuclei via Variation of Mid-infrared Color

At present, there is a lack of effective probes to distinguish between mid-infrared (MIR) outbursts induced by tidal disruption events (TDEs) and changing-look active galactic nuclei (CLAGNs) based on only MIR data. Here, we propose that the time variation of MIR color (K-corrected W1-W2 after subtracting the quiescent fluxes) is a promising probe. With an optically selected sample containing TDEs, ambiguous nuclear transients (ANTs), and CLAGNs, we studied the MIR color variation of their MIR counterparts using NEOWISE-R data. We found that the MIR color of TDEs and ANTs turns red faster than CLAGNs during the rising phase, and TDEs have a redder color than ANTs at the earliest phase. The former may be caused by the difference between the ultraviolet light curves of TDEs/ANTs and CLAGNs, or be related to no or relatively weak underlying AGN in TDEs/ANTs, while the latter may be related to the difference in the dust geometry. Based on color variation rate, we selected high-probability TDE, ANT, and CLAGN candidates from MIR outbursts in samples of Jiang et al. (2021) and Masterson et al. (2024). We found that both samples are mixtures of TDEs/ANTs and CLAGNs. For MIR outbursts whose hosts are not Seyfert galaxies, we estimated that $\sim50\%-80\%$ are TDEs and inferred a rate of infrared TDEs of $1.5-2.8\times10^{-5}$ galaxy$^{-1}$ yr$^{-1}$, comparable with that of optical TDEs. The rest are CLAGNs, suggesting the presence of weak AGNs that cannot be identified using common diagnoses. We predicted that with our method, a large amount of dust-obscured TDEs could be selected from future infrared surveys with higher data quality and cadence.

astro-ph.HE↗

arXiv2025

A Novel Bayesian Extrapolation Design for Assessing Equivalence in Exposure-Response Curves between Pediatric and Adult Populations

Development of effective treatments in pediatric population poses unique scientific and ethical challenges in addition to the small population. In this regard, both the U.S. and E.U. regulations suggest a complementary strategy, pediatric extrapolation, based on assessing the relevance of existing information in the adult population to the pediatric population. The pediatric extrapolation approach often relies on data extrapolation from adults, contingent upon evidence of similar disease progression, pharmacology and clinical response to treatment between adult and children. Similarity evaluation in pharmacology is usually characterized through the exposure-response relationship. Current methodologies for comparing exposure-response (E-R) curves between these groups are inadequate, typically focusing on isolated data points rather than the entire curve spectrum (Zhang et al., 2021). To overcome this limitation, we introduce an innovative Bayesian approach for a comprehensive evaluation of E-R curve similarities between adult and pediatric populations. This method encompasses the entire curve, employing logistic regression for binary endpoints. We have developed an algorithm to determine sample size and key design parameters, such as the Bayesian posterior probability threshold, and utilize the maximum curve distance as a measure of similarity. Integrating Bayesian and frequentist principles, our approach involves developing a method to simulate datasets under both null and alternative hypotheses, allowing for type I error and type II error control. Simulation studies and sensitivity analyses demonstrate that our method maintains a stable performance with type I error and type II error control.

stat.AP↗

arXiv2023

Considerations for Master Protocols Using External Controls

There has been an increasing use of master protocols in oncology clinical trials because of its efficiency and flexibility to accelerate cancer drug development. Depending on the study objective and design, a master protocol trial can be a basket trial, an umbrella trial, a platform trial, or any other form of trials in which multiple investigational products and/or subpopulations are studied under a single protocol. Master protocols can use external data and evidence (e.g., external controls) for treatment effect estimation, which can further improve efficiency of master protocol trials. This paper provides an overview of different types of external controls and their unique features when used in master protocols. Some key considerations in master protocols with external controls are discussed including construction of estimands, assessment of fit-for-use real-world data, and considerations for different types of master protocols. Similarities and differences between regular randomized controlled trials and master protocols when using external controls are discussed. A targeted learning-based causal roadmap is presented which constitutes three key steps: (1) define a target statistical estimand that aligns with the causal estimand for the study objective, (2) use an efficient estimator to estimate the target statistical estimand and its uncertainty, and (3) evaluate the impact of causal assumptions on the study conclusion by performing sensitivity analyses. Two illustrative examples for master protocols using external controls are discussed for their merits and possible improvement in causal effect estimation.

stat.AP↗

arXiv2023

UAV Deployment Optimization for Secure Precise Wireless Transmission

This paper develops an unmanned aerial vehicle (UAV) deployment scheme in the context of the directional modulation-based secure precise wireless transmissions (SPWTs), where the optimal UAV position for the SPWT is derived to maximum the secrecy rate (SR) without injecting any artificial noise (AN) signaling. To be specific, the proposed scheme reveals that the optimal position of UAV for maximizing the SR performance has to be placed at the null space of Eves channel, which impels the received energy of the confidential message at the unintended receiver deteriorating to zero whilst benefits the one at the intended receiver achieving its maximum value. Finally, simulation results verify the optimality of our proposed scheme in terms of the achievable SR performance.

eess.SP↗

arXiv2022

Extent of Safety Database in Pediatric Drug Development: Types of Assessment, Analytical Precision, and Pathway for Extrapolation through On-Target Effects

Pediatric patients should have access to medicines that have been appropriately evaluated for safety and efficacy. Given this goal of revised labelling, the adequacy of the pediatric clinical development plan and resulting safety database must inform a favorable benefit-risk assessment for the intended use of the medicinal product. While extrapolation from adults can be used to support efficacy of drugs in children, there may be a reluctance to use the same approach in safety assessments, wiping out potential gains in trial efficiency through a reduction of sample size. To address this reluctance, we explore safety review in pediatric trials, including factors affecting these data, specific types of safety assessments, and precision on the estimation of event rates for specific adverse events (AEs) that can be achieved. In addition, we discuss the assessments which can provide a benchmark for the use of extrapolation of safety that focuses on on-target effects. Finally, we explore a unified approach for understanding precision using Bayesian approaches as the most appropriate methodology to describe/ascertain risk in probabilistic terms for the estimate of the event rate of specific AEs.

stat.AP↗